TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) swung into profit last year with net profit of NT$775 million (US$27.1 million) after it received a bonus payment from China’s Zhejiang Medicine Co (浙江醫藥集團), it said yesterday.
Last year marked TaiGen’s first profitable year since 2017, as it registered net losses of NT$343 million in 2018, NT$295 million in 2019 and NT$404 million in 2020.
Despite reporting earnings per share of NT$1.08 for last year, the company’s board of directors has proposed not to distribute a cash dividend this year, TaiGen said.
The company attributed the improvement in its balance sheet to a payment of NT$1.29 billion from Zhejiang Medicine to buy TaiGen’s Chinese patent of its antibacterial drug Taigenxyn (nemonoxacin).
The money was used to develop the new experimental anti-influenza drug TG-1000 and a new antibiotic for a drug-resistant bacterium, the company said in a statement.
“We are still compiling the data generated in our phase 2 clinical trials for TG-1000, so it will take a while before we reveal the results,” TaiGen chairman Philip Huang (黃國龍) said in the statement.
TaiGen finished recruiting all 202 participants for human tests last month.
The company would determine the overseas market for the development of TG-1000 after phase 2 human trials are completed, Huang said.
Although the phase 2 tests are being conducted in China, the test results can be used to file an application with the US Food and Drug Administration, as the protocols of the tests meet the agency’s requirements, Huang said earlier this year.
This time was supposed to be different. The memorychip sector, famous for its boom-and-bust cycles, had changed its ways. A combination of more disciplined management and new markets for its products — including 5G technology and cloud services — would ensure that companies delivered more predictable earnings. Yet, less than a year after memory companies made such pronouncements, the US$160 billion industry is suffering one of its worst routs ever. There is a glut of the chips sitting in warehouses, customers are cutting orders and product prices have plunged. “The chip industry thought that suppliers were going to have better control,” said
Enimmune Corp (安特羅生技) has obtained marketing approval from the Food and Drug Administration (FDA) for its EnVAX-A71 vaccine for enterovirus 71 (EV-71), becoming the nation’s first enterovirus vaccine completely made in Taiwan, it said yesterday. After spending 13 years and NT$1.5 billion (US$49.77 million) on the research and development of the vaccine, Enimmune plans to start manufacturing and marketing it by the end of March, the company said in a statement, without disclosing customer order figures. “It is possible that the vaccine would not be included in a national vaccination program initially, and consumers would need to pay for it themselves,” parent
Hon Hai Technology Group (鴻海科技集團), also known as Foxconn Technology Group (富士康科技集團) internationally, yesterday said it was confident that its performance would improve in the second half of this year. Investment plans related to electric vehicles (EVs) in different parts of the world are expected to gradually start coming to fruition, Hon Hai chairman Young Liu (劉揚偉) told reporters after leading a new year’s prayer at the company’s headquarters in New Taipei City’s Tucheng District (土城). Major challenges stemming from the COVID-19 pandemic and the Russia-Ukraine war continue to affect the global economy. However, Liu said that he expects a turnaround in
Singapore is seeing an influx of ultra-wealthy families from China looking to protect their wealth from a government that increasingly views them with suspicion. The Chinese Communist Party’s recent crackdowns on tech billionaires and tax-shy celebrities, as well as three years of “zero COVID” policies, have led many rich Chinese to look for a safe haven. Nervous over the fate of their fortunes, some of the country’s mega-rich have since booked tickets to Singapore, insiders said. The key Asian financial hub ticks all the boxes for relocating tycoons. Singapore has been ruled by one party for the past six decades, and labor strikes and
RSS